FDA Rejects Replimune's Melanoma Drug Again, Cementing Stricter Stance Under New Leadership

The FDA has delivered a second, decisive rejection to Replimune Group's experimental treatment for advanced melanoma, solidifying the therapy's status as a flashpoint in a high-stakes debate over regulatory standards. This engineered virus, designed to activate the immune system against skin cancer, was initially turned down in July. The latest refusal underscores a persistent and significant regulatory hurdle for the company and signals a potentially enduring shift in the agency's approval philosophy.

The rejection comes under the leadership of Vinay Prasad, the academic oncologist appointed to head the FDA's biologics division just two months before the first denial. Prasad has been a vocal critic of drug approvals based on limited data, and the Replimune decision is widely viewed as a direct reflection of his stricter stance. This move places intense pressure on Replimune, forcing it back to the drawing board for a treatment that once represented a promising frontier in cancer immunotherapy.

The repeated rejection amplifies scrutiny on the FDA's evolving benchmarks for clinical evidence, particularly for novel biologic therapies. It serves as a clear warning to other biotech firms developing similar innovative treatments: the regulatory pathway may now demand more robust data. This development risks chilling investment and research in certain cutting-edge oncology approaches, as the industry recalibrates to meet what appears to be a new, more rigorous standard at the agency.